الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vírus varicella-zoster (živý, zoslabený) - herpes zoster; immunization - vírusové vakcíny - zostavax je indikovaný na prevenciu pásového oparu ("zoster" alebo šindle) a súvisiace s herpes zoster postherpetická neuralgia. zostavax je indikovaný na imunizácie jednotlivcov 50 rokov alebo starší.

سلوفاكيا - السلوفاكية - ŠÚKL (Štátny ústav pre kontrolu liečiv)

merck sharp & dohme b.v., holandsko - očkovacia látka proti vírusu varicella, živá oslabená - 59 - immunopraeparata

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vírus, živý oslabený, osýpky, vírus, živý oslabený, príušnica, vírus, živý oslabený, rubeola, vírus, živý oslabený, ovčie kiahne - chickenpox; rubella; measles; mumps; immunization - vakcíny - proquad je indikovaný na súčasné očkovanie proti osýpkam, mumpsu, rubeole a ovčím kiahňam u jedincov vo veku od 12 mesiacov. proquad môžu byť podávané na jednotlivcov od 9 mesiacov veku za osobitných okolností (e. , v súlade s vnútroštátnymi očkovania plány, ohnisko situáciách, alebo cestovať do oblasti s vysokou prevalenciou osýpky.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimykotika na systémové použitie - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invázne aspergillosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo itraconazole alebo u pacientov, ktorí netolerujú týchto liekov;- fusariosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo u pacientov, ktorí netolerujú z amphotericin b;- chromoblastomycosis a mycetoma u pacientov s ochorením, ktoré je žiaruvzdorných na itraconazole alebo u pacientov, ktorí netolerujú z itraconazole;- kokcidiomykóza u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b, itraconazole alebo fluconazol alebo u pacientov, ktorí netolerujú týchto liekov;- oropharyngeal kandidóza: ako v prvej línii liečby u pacientov, ktorí majú závažné ochorenie alebo sú imunokompromitovaných, v ktorých reakcie na aktuálne terapia sa očakáva, že byť chudobným. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika na systémové použitie - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - indinavirom sulfát ethanolate - hiv infekcie - antivirotiká na systémové použitie - crixivan je indikovaný v kombinácii s antiretrovírusovými nukleozidovými analógmi na liečbu dospelých infikovaných hiv-1.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - bezlotoxumab - enterokolitída, pseudomembranózna - imunitný séra a imunoglobulíny, - zinplava je indikovaná na prevenciu recidívy infekcie clostridium difficile (cdi) u dospelých s vysokým rizikom recidívy cdi.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokové infekcie - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. pozri časti 4. 4 a 5. 1 pre informácie o ochrane proti špecifickým pneumokokovým sérotypom. the use of vaxneuvance should be in accordance with official recommendations.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v. - gefapixant - cough - prípravky proti kašľu a chladu - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

الاتحاد الأوروبي - السلوفاكية - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ľudským papilomavírusom typu 6 l1 bielkovín, ľudským papilomavírusom typu 11 l1 bielkovín, ľudským papilomavírusom typu 16 l1 bielkovín, ľudským papilomavírusom typu 18 l1 bielkovín - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vakcíny - gardasil je vakcína pre použitie od veku 9 rokov na prevenciu:premalignant genitálny lézie (krčná, vulvar a vaginálny), premalignant análny lézie, krčka maternice a rakoviny análneho príčinne spojené s určitými oncogenic Ľudský papilomavírus (hpv) typy;genitálne bradavice (condyloma acuminata) príčinne spojené s konkrétnym hpv typy. pozri časti 4. 4 a 5. 1 pre dôležité informácie o údajoch, ktoré podporujú túto indikáciu. použitie gardasil by mali byť v súlade s oficiálne odporúčania.